| This week's sponsor is Premier Research. | | | How Psoriasis Treatment Advanced, and What's Next
Thanks to new biologics, more than half of treated psoriasis patients achieve essentially clear skin. Our white paper examines how we got here, and what's next. Premier Research. It's what we do. Best. |
Today's Rundown Allergan pads women’s health pipeline with Repros buyout Spark’s hemophilia A data causes investor jitters Vertex licenses blood disorder gene therapy from CRISPR Therapeutics [Sponsored] How Real - World Evidence and Value-Based Contracts Can Help Payers and Manufacturers Find Common Ground in Rare Disease PsiOxus banks first milestone for BMS-backed cancer therapy Ex-Dezima executives scoop €25M for midphase NASH trial 'Epigenetic CRISPR' edits DNA without cutting it Featured Story | | | Tuesday, December 12, 2017 Allergan has struck a deal to acquire the floundering Repros Therapeutics. The bargain-basement takeout gives Allergan the rights to a uterine fibroid drug that is on the cusp of phase 3, but also responsibility for compiling the large safety database the FDA wants to see before signing off on further development. |
|
|
| This week's sponsor is FierceBiotech. | | | |
Top Stories Tuesday, December 12, 2017 Just over a week ago, Spark Therapeutics was riding high on positive data for its hemophilia B gene therapy. It’s now fallen back to earth after spooking investors with the results of a trial in hemophilia A. Tuesday, December 12, 2017 Vertex Pharmaceuticals is licensing the first CRISPR-based treatment to come out of its $105 million collaboration with CRISPR Therapeutics. The beta-thalassemia and sickle cell disease therapy will enter clinical trials in 2018. Monday, December 11, 2017 When payers and manufacturers brawl over pricing, patients with rare diseases can suffer. Is there any common ground? Both sides believe real-world evidence can help quantify the benefits of a medication, and value-based contracts can ensure patients reap the rewards. Tuesday, December 12, 2017 U.K. biotech PsiOxus Therapeutics has a green light for trials of its cancer-killing virus therapy for solid tumors, sparking a $15 million milestone payment from development partner Bristol-Myers Squibb. Tuesday, December 12, 2017 NorthSea Therapeutics has raised €25 million ($29 million) to put a NASH drug through phase 2b. The round reunites some of the executives and investors who helped Dezima and NASH startup Akarna to takeovers by Amgen and Allergan, respectively. Friday, December 8, 2017 A Salk Institute team created a form of CRISPR/Cas9 that activates specific genes without making breaks in the DNA, which can cut down on harmful side effects. Resources Sponsored by: Seton Hall Don’t miss this educational program trusted by multi-national companies as part of their employee’s compliance training. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating in the Asia-Pacific region. Visit event page for session topics. Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA BIO CEO & Investor Conference February 12-13, 2018 | New York, New York | 